Skip to main content

HubXchange

HubXChange logo

Oligonucleotide Therapeutics Xchange - Boston - 2024

Page Banner 1

  1. Manufacturing
    • Manufacturing
    Novel methodologies to manufacture Oligonucleotides
    Salon C
    Mayur Patel
    Mayur Patel, Director, Oligonucleotides Chemistry - Korro Bio
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    Afternoon Refreshments
    Grand Foyer
  3. Drug Delivery
    • Drug Delivery
    Manufacturing n-of-1 batches ' helping 1 patient at a time? [Manufacturing Topic]
    Salon D
    Manufacturing n-of-1 batches ' helping 1 patient at a time? [Manufacturing Topic]
    Jeremy Little
    Jeremy Little, Director of Custom Oligonucleotides - ChemGenes
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    Evening Drinks Reception
    Grand Foyer
  5. Oligonucleotide Discovery
    • Oligonucleotide Discovery
    Emerging opportunities for liver-targeting and extrahepatic areas.
    Salon B
    Lakshmi Bhagat
    Lakshmi Bhagat, Associate Scientific Director - Luye Pharma Group
  6. New Modalities
    • New Modalities
    Novel new modalities for oligonucleotides.
    Salon A
    Dan Roseman
    Dan Roseman, Associate Director, Analytical CMC Strategy - Bristol-Myers Squibb
  7. Manufacturing
    • Manufacturing
    Poster Session: Untargeted Mass Spectrometry for Precision Oligo Analytics
    Salon C
    Poster Session: Untargeted Mass Spectrometry for Precision Oligo Analytics
    Sumukh Ray
    Sumukh Ray, Principal Scientist, Analytical Development - Bachem
  8. Oligonucleotide Discovery
    • Oligonucleotide Discovery
    Poster Session: XNA-Hub: The First Worldwide Experimentally-Calibrated in-silico Platform to Model and Investigate Natural and Non-Natural Nucleic Acids
    Salon B
    Poster Session: XNA-Hub: The First Worldwide Experimentally-Calibrated in-silico Platform to Model and Investigate Natural and Non-Natural Nucleic Acids
    Vito Genna
    Vito Genna, Director of North America - Nostrum Biodiscovery
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    Spotlight Presentation: mRNA Technology Challenge and Process Scheme
    Salon H
    Spotlight Presentation: mRNA Technology Challenge and Process Scheme
     
    Tianqi Min
    Tianqi Min, Director - Vazyme
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    1-2-1 Meetings/Networking Break
    1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    1-2-1 Meetings/Networking Break
    1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    Networking Lunch
    Thomson Hall - First Floor
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    Opening Address & Keynote Presentation: Thiophosphoramidate Morpholino Oligonucleotides: A novel class of PMOs compatible with conventional automated ON synthesis.
    Salon H
    Opening Address & Keynote Presentation: Thiophosphoramidate Morpholino Oligonucleotides: A novel class of PMOs compatible with conventional automated ON synthesis.
  14. New Modalities
    • New Modalities
    Strategies for Production of Oligonucleotide Conjugates [Manufacturing Topic]
    Salon A
    Strategies for Production of Oligonucleotide Conjugates [Manufacturing Topic]
    Effect of conjugation site on process Impact of conjugate on chromatography Analytical implications
    Benjamin Thompson, Ph.D.
    Benjamin Thompson, Ph.D., Process Development Project Leader - Nitto Avecia
  15. Manufacturing
    • Manufacturing
    Current challenges for drug substance CDMOs in the Oligonucleotide space.
    Salon C
    Current challenges for drug substance CDMOs in the Oligonucleotide space.
    Trishul Shah
    Trishul Shah, Director Business Development, Head of Sales North America - PolyPeptide
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    Morning Refreshments
    Grand Foyer
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    1-2-1 Meetings/Networking Break
    1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    1-2-1 Meetings/Networking Break
    1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
  19. Oligonucleotide Discovery
    • Oligonucleotide Discovery
    Novel oligonucleotide drug delivery approaches.
    Salon B
    Harsh Chauhan
    Harsh Chauhan, Director, Formulation Development and External Manufacturing - Alltrna
    • New Modalities
    • Oligonucleotide Discovery
    • Manufacturing
    • Drug Delivery
    Registration
    Grand Foyer
  21. New Modalities
    • New Modalities
    New formats / chemical modifications for antisense therapeutics
    Salon A
     
    Vinod Vathipadiekal
    Vinod Vathipadiekal, Board Director - Aldebaran Therapeutics
  22. Drug Delivery
    • Drug Delivery
    How to speed up oligonucleotide drug candidates selection
    Salon B
    Zhinan Xia
    Zhinan Xia, Chief Scientific Officer - Abimmune Bio
  23. Manufacturing
    • Manufacturing
    Downstream manufacturing challenges for synthetic oligonucleotides.
    Salon C
     
    Firoz Antia
    Firoz Antia, Executive Director, Head of Oligonucleotide Development - Biogen
Search